Introduction: Diffuse myocardial fibrosis is a negative CV prognostic marker. We employed advanced cardiac MRI (CMR) techniques for detailed left ventricular myocardial tissue characterization people with type 1 diabetes (PwT1D) and high CV risk.

Methods: Quantitative native T1 mapping (T1) and extracellular volume fraction (ECV) calculation of the whole left ventricular myocardial volume (LVMV) was done (1.5T Avanto Fit, Siemens) in PwT1D and high CV risk (CAC score >400 and/or presence of ≥2 atherosclerotic plaques in the carotids) but without clinical diagnosis of CVD or heart failure. Percentage of LVMV above the normal values for T1 (>1100 ms) and ECV (>28 %) was calculated.

Results: Twelve PwT1D (8/12 women) with mean (SD) [range] age 65 (2) [60 - 67] years, diabetes duration 36 (12) [16 - 56] years, HbA1c 7.5 (0.9) [6.0 - 8.8] %, LV EF 66 (7) [54 - 77] % were analyzed. Mean (SD) [range] native T1 time was 1060 (41) [996 - 1138] ms and the % of LVMV >1100 ms was 27 (11) [14 - 47] % (Fig. 1A). Mean (SD) [range] ECV was 28.6 (3.5) [23 - 33] % and the % of LVMV >28 % was 47 (21) [7 - 78] % (Fig. 1B).

Conclusion: This is the first CMR study which has applied threshold values to native T1 and ECV data for the whole LVMV in PwT1D. We demonstrate large myocardial areas which are above the normal values. Clinical implications of our findings will require further evaluation on larger populations.

graphic
View largeDownload slide
Disclosure

P. Novodvorsky: Speaker's Bureau; Sanofi, Boehringer-Ingelheim. Advisory Panel; Boehringer-Ingelheim. Speaker's Bureau; Novo Nordisk A/S. Research Support; Sanofi. Speaker's Bureau; Abbott, Medtronic, Berlin-Chemie AG, Viatris Inc., Novartis AG. M. Dubsky: None. N. Marhefková: None. T. Adla: None. R. Roland: None. M. Pazdernik: None. M. Haluzik: Advisory Panel; Sanofi, Novo Nordisk, Eli Lilly and Company, AstraZeneca, Bayer Inc., Johnson & Johnson Medical Devices Companies. Consultant; Merck & Co., Inc., Sanofi, Novo Nordisk, Eli Lilly and Company, AstraZeneca, Bayer Inc., Boehringer-Ingelheim, Johnson & Johnson Medical Devices Companies, Novatin. Research Support; Sanofi. Speaker's Bureau; Sanofi, Novo Nordisk. P. Garg: Consultant; Edwards Lifesciences, Anteris. Advisory Panel; Pie Medical, Medis.

Funding

National Institute for Research of Metabolic and Cardiovascular Diseases (Programme EXCELES, Project No. LX22NPO5104); Funded by the European Union; Next Generation EU

© 2024 by the American Diabetes Association
2024
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.